Prostate Cancer Foundation Issues $4.5 Million in Grants to Support Innovation from Young Investigators
News Apr 22, 2010
The Prostate Cancer Foundation (PCF) has announced the funding of 21 new Young Investigator Awards at 17 leading cancer centers in the U.S. and Canada. Designed to encourage the innovative minds in cancer research to focus their careers on prostate cancer, the awards provide recipients with three years of funding to test transformational research questions for prostate cancer patients.
The 2010 Young Investigator Awards represent a new $4.5 million investment in the global cancer research community by PCF.
With the announcement of the 2010 Young Investigators, PCF is now funding 43 research projects led by young investigators around the world. These Young Investigator projects are three years in duration. Each award is $225,000 total and is matched dollar for dollar or matched in kind by the recipients’ research institutions, making the total award worth $450,000 in support.
“We are investing in the careers of the world’s ‘best of the best’ in computer science, molecular biology, pharmacology, radiation oncology, medical oncology and endocrinology to answer the challenge of discovering better treatments and cures for prostate cancer,” commented Howard R. Soule, PhD, executive vice president and chief science officer for PCF.
“The research mentors of these Young Investigators are as expert, accomplished and committed as we have ever seen,” said Jonathan W. Simons, MD, president and CEO of PCF. “We look forward to seeing the contributions these young scientists will make in our field.”
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
New Preservation Method Maintains Viable CTCs for up to 72 HoursNews
A new blood stabilization method significantly prolongs the lifespan of blood samples for microfluidic sorting and transcriptome profiling of rare circulating tumor cells.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018